Application and timing of hemoperfusion therapy for sepsis

doi:10.3877/cma.j.issn.2096-1537.2026.02.016

Abstract

Abstract:

Sepsis is a common and critical illness in the intensive care unit (ICU) with high mortality, and remains a major challenge in clinical practice. Hemoperfusion, a blood purification method based on adsorption that removes either endogenous or exogenous toxins and pathogens, has attracted more and more interest for its therapeutic possibilities in the management of sepsis. This paper summarizes the mechanism and current application of hemoperfusion in sepsis treatment, with a particular focus on the timing of treatment. Early initiation and relatively prolonged continuous hemoperfusion may be quite helpful for individuals with moderate to severe sepsis requiring vasopressors.

Key words: Hemoperfusion, Sepsis, Application, Timing selection

Xianglong Cai, Guoqiang Li, Liangliang Liu, Yin Zhang. Application and timing of hemoperfusion therapy for sepsis[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(02): 189-195.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://icu.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-1537.2026.02.016

https://icu.cma-cmc.com.cn/EN/Y2026/V12/I02/189

Figures/Tables 1

References 57

1	Perner A, Cecconi M, Cronhjort M, et al. Expert statement for the management of hypovolemia in sepsis [J]. Intensive Care Med, 2018, 44(6): 791-798.
2	Xie J, Wang H, Kang Y, et al. The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey [J]. Crit Care Med, 2020, 48(3): e209-e218.
3	唐立丽, 龚模祥, 陈荍, 等. Maresin-1对脓毒症器官保护作用的研究进展 [J]. 中华危重病急救医学, 2024, 36(2): 211-215.
4	Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 [J]. Intensive Care Med, 2021, 47(11): 1181-1247.
5	Ronco C, Chawla L, Husain-Syed F, et al. Rationale for sequential extracorporeal therapy (SET) in sepsis [J]. Crit Care, 2023, 27(1): 50.
6	Tani T, Shimizu T, Tani M, et al. Anti-endotoxin properties of Polymyxin B-immobilized fibers [J]. Adv Exp Med Biol, 2019, 1145: 321-341.
7	Nishibori M, Takahashi H, Katayama H, et al. Specific removal of monocytes from peripheral blood of septic patients by Polymyxin B-immobilized filter column [J]. Acta Med Okayama, 2009, 63(1): 65-69.
8	Cotoia A, Parisano V, Mariotti PS, et al. Kinetics of different blood biomarkers during Polymyxin B extracorporeal hemoperfusion in abdominal sepsis [J]. Blood Purif, 2024, 53(7): 1-9.
9	Coudroy R, Payen D, Launey Y, et al. Modulation by Polymyxin B hemoperfusion of inflammatory response related to severe peritonitis [J]. Shock, 2017, 47(1): 93-99.
10	Oshima K, Akao T, Kobayashi K, et al. The effect of direct hemoperfusion with a Polymyxin B-immobilized fiber column (DHP-PMX therapy) on pulmonary ischemia-reperfusion injury in a canine model [J]. J Invest Surg, 2008, 21(3): 127-132.
11	Jansen A, Waalders NJB, van Lier DPT, et al. CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo [J]. Crit Care, 2023, 27(1): 117.
12	李世明, 黄蔚, 刘玲. HMGB1介导脓毒症相关凝血功能障碍的作用机制及其治疗进展 [J/OL]. 中华重症医学电子杂志, 2023, 9(3): 269-273.
13	Gruda MC, Ruggeberg KG, O'Sullivan P, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb^® sorbent porous polymer beads [J]. PLoS One, 2018, 13(1): e0191676.
14	Zhou J, Li H, Zhang L, et al. Removal of inflammatory factors and prognosis of patients with septic shock complicated with acute kidney injury by hemodiafiltration combined with HA330-Ⅱ hemoperfusion [J]. Ther Apher Dial, 2024, 28(3): 460-466.
15	俞国峰, 吕铁, 陆地, 等. 血液灌流对脓毒性休克高迁移率族蛋白B-1清除效果的研究 [J]. 中华医院感染学杂志, 2019, 29(1): 23-26, 35.
16	Kaçar CK, Uzundere O, Kandemir D, et al. Efficacy of HA330 hemoperfusion adsorbent in patients followed in the intensive care unit for septic shock and acute kidney injury and treated with continuous venovenous hemodiafiltration as renal replacement therapy [J]. Blood Purif, 2020, 49(4): 448-456.
17	Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices [J]. Intensive Care Med Exp, 2018, 6(1): 12.
18	Hellman T, Uusalo P, Järvisalo MJ. Renal replacement techniques in septic shock [J]. Int J Mol Sci, 2021, 22(19): 10238.
19	Wendel Garcia PD, Hilty MP, Held U, et al. Cytokine adsorption in severe, refractory septic shock [J]. Intensive Care Med, 2021, 47(11): 1334-1336.
20	Lee JM, Baek SD, Kim TH, et al. Uncertain clinical effect of Polymyxin B hemoperfusion in patients with septic acute kidney injury requiring continuous renal replacement therapy [J]. Shock, 2021, 56(4): 551-556.
21	Akil A, Ziegeler S, Reichelt J, et al. Combined use of CytoSorb and ECMO in patients with severe pneumogenic sepsis [J]. Thorac Cardiovasc Surg, 2021, 69(3): 246-251.
22	Rugg C, Klose R, Hornung R, et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective 'genetic' matched analysis [J]. Biomedicines, 2020, 8(12): 539.
23	Brouwer WP, Duran S, Kuijper M, et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study [J]. Crit Care, 2019, 23(1): 317.
24	Garcia-Ramos S, Caamaño E, Rodríguez Benítez P, et al. Mortality risk prediction in abdominal septic shock treated with Polymyxin B hemoperfusion: a retrospective cohort study [J]. J Pers Med, 2023, 13(7): 1023.
25	Klein DJ, Foster D, Walker PM, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial [J]. Intensive Care Med, 2018, 44(12): 2205-2212.
26	Cho A, Oh SY, Lee H, et al. Vasopressor reduction effect of Polymyxin B hemoperfusion in patients with peritonitis-induced septic shock: a propensity score-matched analysis [J]. Shock, 2024, 62(1): 69-73.
27	Stockmann H, Thelen P, Stroben F, et al. CytoSorb rescue for COVID-19 patients with vasoplegic shock and multiple organ failure: a prospective, open-label, randomized controlled pilot study [J]. Crit Care Med, 2022, 50(6): 964-976.
28	Dirk S, Christine P, Daniel H, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial [J]. PLoS One, 2017, 12(10): e0187015.
29	Akil A, Ziegeler S, Rehers S, et al. Blood purification therapy in patients with severe COVID-19 requiring veno-venous ECMO therapy: a retrospective study [J]. Int J Artif Organs, 2022, 45(7): 615-622.
30	Kogelmann K, Scheller M, Drüner M, et al. Use of hemoadsorption in sepsis-associated ECMO-dependent severe ARDS: a case series [J]. J Intensive Care Soc, 2020, 21(2): 183-190.
31	Rachoin JS, Foster D, Giese R, et al. Importance of endotoxin clearance in endotoxemic septic shock: an analysis from the evaluating use of Polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemic septic shock (EUPHRATES) trial [J]. Crit Care Explor, 2020, 2(2): e0083.
32	Sekino M, Murakami Y, Sato S, et al. Modifications of peripheral perfusion in patients with vasopressor-dependent septic shock treated with Polymyxin B-direct hemoperfusion [J]. Sci Rep, 2023, 13(1): 7295.
33	Fujimori K, Tarasawa K, Fushimi K. Effectiveness of Polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study [J]. Ann Intensive Care, 2021, 11(1): 141.
34	Lee WY, Kim HJ, Kim EY. Impact of Polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study [J]. Sci Rep, 2021, 11(1): 24132.
35	Fujimori K, Tarasawa K, Fushimi K. Effects of Polymyxin B hemoperfusion on septic shock patients requiring noradrenaline: analysis of a nationwide administrative database in Japan [J]. Blood Purif, 2021, 50(4-5): 560-565.
36	Hawchar F, Tomescu D, Träger K, et al. Hemoadsorption in the critically ill-final results of the International CytoSorb Registry [J]. PLoS One, 2022, 17(10): e0274315.
37	Chang T, Tu YK, Lee CT, et al. Effects of Polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, Meta-analysis update, and disease severity subgroup Meta-analysis [J]. Crit Care Med, 2017, 45(8): e858-e864.
38	田兴国, 陈志, 贺慧为, 等. 多黏菌素B血液灌流对脓毒症和脓毒症休克患者预后影响的荟萃分析 [J]. 中国呼吸与危重监护杂志, 2020, 19(1): 16-21.
39	Chen JJ, Lai PC, Lee TH, et al. Blood purification for adult patients with severe infection or sepsis/septic shock: a network Meta-analysis of randomized controlled trials [J]. Crit Care Med, 2023, 51(12): 1777-1789.
40	Mehta Y, Mehta C, Kumar A, et al. Experience with hemoadsorption (CytoSorb(®)) in the management of septic shock patients [J]. World J Crit Care Med, 2020, 9(1): 1-12.
41	Nakata H, Yamakawa K, Kabata D, et al. Identifying septic shock populations benefitting from Polymyxin B hemoperfusion: a prospective cohort study incorporating a restricted cubic spline regression model [J]. Shock, 2020, 54(5): 667-674.
42	Friesecke S, Stecher SS, Gross S, et al. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study [J]. J Artif Organs, 2017, 20(3): 252-259.
43	Gabriella B, Isabella G, Marco M, et al. Hemoperfusion with CytoSorb in pediatric patients with septic shock: a retrospective observational study [J]. Int J Artif Organs, 2020, 43(9): 587-593.
44	Fatime H, Ildikó L, Nándor Ö, et al. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study [J]. J Crit Care, 2018, 49: 172-178.
45	Honore PM, Hoste E, Molnar Z, et al. Cytokine removal in human septic shock: where are we and where are we going? [J]. Ann Intensive Care, 2019, 9(1): 56.
46	Paul R, Sathe P, Kumar S, et al. Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb(®)) in patients with sepsis and septic shock [J]. World J Crit Care Med, 2021, 10(1): 22-34.
47	Kogelmann K, Hübner T, Schwameis F, et al. First evaluation of a new dynamic scoring system intended to support prescription of adjuvant CytoSorb hemoadsorption therapy in patients with septic shock [J]. J Clin Med, 2021, 10(13): 2939.
48	Tanaka T, Tabata T, Fujino K, et al. "Impact of timing of Polymyxin B-immobilized fiber column direct hemoperfusion on outcome in patients with septic shock: a single-center observational study" [J]. Acute Med Surg, 2020, 7(1): e446.
49	Yamato M, Asahina Y, Koizumi S, et al. Lactate predicts the 28-day survival rate in patients with septic shock treated with the combination of PMX-DHP and rTM [J]. Ther Apher Dial, 2020, 24(5): 492-498.
50	Brouwer WP, Duran S, Ince C. Improved survival beyond 28 days up to 1 year after CytoSorb treatment for refractory septic shock: a propensity-weighted retrospective survival analysis [J]. Blood Purif, 2021, 50(4-5): 539-545.
51	Berlot G, Samola V, Barbaresco I, et al. Effects of the timing and intensity of treatment on septic shock patients treated with CytoSorb^®: Clinical experience [J]. Int J Artif Organs, 2022, 45(3): 249-253.
52	Mitaka C, Kusao M, Kawagoe I, et al. Impact of extended duration of Polymyxin B-immobilized fiber column direct hemoperfusion on hemodynamics, vasoactive substance requirement, and pulmonary oxygenation in patients with sepsis: an observational study [J]. Blood Purif, 2022, 51(1): 62-69.
53	Romaschin AD, Obiezu-Forster CV, Shoji H, et al. Novel insights into the direct removal of endotoxin by Polymyxin B hemoperfusion [J]. Blood Purif, 2017, 44(3): 193-197.
54	Biever P, Staudacher DL, Sommer MJ, et al. Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19 [J]. Pharmacol Res Perspect, 2021, 9(2): e00743.
55	Schneider AG, André P, Scheier J, et al. Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption [J]. Sci Rep, 2021, 11(1): 10493.
56	Lebreton G, Dorgham K, Quentric P, et al. Longitudinal cytokine profiling in patients with severe COVID-19 on extracorporeal membrane oxygenation and hemoadsorption [J]. Am J Respir Crit Care Med, 2021, 203(11): 1433-1435.
57	Zhang X, Chen H, Feng L, et al. Central venous catheters misplaced in paraspinal veins: a systematic literature review based on case reports [J]. Nurs Crit Care, 2021, 26(4): 262-273.

研究作者	年份	地点	研究设计	干预/样本量	类型/亚组	主要发现
Klein DJ，et al ^［25］	2018	北美	RCT	PMX-HP/450例	脓毒性休克/EAA≥0.60，0.60~0.89（MODS≥9分），≥0.90	总体：28 d病死率、EAA无差异；0.60~0.89组：PMX-HP组28 d病死率、90 d病死率更低，MAP更高、VFDs更长，并依据NE是否＞0.1 μg/（kg•min）再分亚组，NE＞0.1 μg/（kg•min）组病死率也更低
Rachoin JS，et al ^［31］	2020	北美	RCT	PMX-HP/450例	脓毒性休克/EAA≥0.6，0.6~0.9（MODS≥9分），＞0.9	总体：28 d病死率、EAA无差异；0.6~0.9组：PMX-HP组，如第3天EAA≤0.65，28 d病死率更低，如第3天EAA降幅＞10.4%（中位数），VFDs更长，PAR改善更明显
Sekino M，et al ^［32］	2023	日本	回顾性探索性观察研究	PMX-HP/122例	脓毒性休克/PAI ＜1（外周灌注正常组），≥1（外周灌注异常组）	总体：两组VIS、CVP、心率、乳酸水平降低；亚组：外周灌注正常组与异常组28 d病死率、住院病死率无差异（异常组病死率应更高），异常组PAI明显改善，正常组改善不明显（但PAI≥1组PMX-HP开始时间更早）
Garcia-Ramos S，et al ^［24］	2023	西班牙	队列研究	PMX-HP/93例	腹部脓毒性休克/SOFA（分） 0~7，8~13，＞13	总体：实际30 d病死率低于APACHE Ⅱ所预测的病死率；亚组：SOFA 8~13分组实际病死率显著低于预测病死率，而其他两组实际与预测病死率无差异。
Fujimori K，et al ^［33］	2021	日本	队列研究	PMX-HP/4066例	脓毒症/SOFA（分） 0~6，7~9，10~12，13~15，16~24	亚组：7~12分的2组28 d病死率更低，其他分组无差异；0~12分的3组无CHDF时间更长，7~12分2组VFDs、无NE时间更长；SOFA组成成分中呼吸、凝血、肝脏、心血管和肾脏高评分组（≥2分），28 d病死率更低
Lee W Y，et al ^［34］	2021	韩国	队列研究	PMX-HP/60例	腹部脓毒症（已手术）/EA＜0.54，≥0.54	总体：PMX-HP组未显示生存获益；亚组：EA≥0.54组，EA下降更明显，多因素Logistics分析显示PMX-HP对EA≥0.54组有生存益处，而对EA＜0.54组无生存益处
Fujimori K，et al ^［35］	2021	日本	队列研究	PMX-HP/8282例	脓毒性休克/NE日最大剂量（mg/d）＜6，6~9.9，10~19.9，＞20	总体：PMX-HP组28 d病死率降低，无CHDF、NE、MV天数延长；亚组：＜19.9 mg/d的3组PMX-HP有生存益处，其中10~19.9 mg/d组比值比最高，＞20 mg/d组未显示生存益处
Hawchar F，et al ^［36］	2022	多国	病例系列研究	CytoSorb/936例	脓毒症/APACHE Ⅱ（分）＜30，≥30	总体：实际ICU病死率与APACHEⅡ所预测的病死率无差异，CRP、PCT下降；亚组：15~25分组实际ICU病死率高于预测的病死率，而≥30分组实际ICU病死率低于预测
Chang T，et al ^［37］	2017	多国	Meta分析	PMX-HP/1332例	脓毒症/常规治疗组病死率（%）＜30%，30%~60%，＞60%	总体：病死率降低，但在RCT研究的分组Meta分析中未观察到此情况；亚组：中、高死亡风险组（常规治疗组病死率≥30%）病死率显著降低（但论文中病死率指标不统一，证据质量偏低）
田兴国，等^［38］	2020	多国	Meta分析	PMX-HP/926例	脓毒症/中重度脓毒性休克	总体：不能降低28 d病死率；亚组：PMX-HP治疗使中重度脓毒性休克组28 d病死率降低（仅纳入4个RCT研究，且异质性过大，且未明确中重度脓毒性休克的评价标准，证据质量偏低）
Chen JJ，et al ^［39］	2023	多国	网状Meta分析	17种方式/4595例	严重感染、脓毒症、脓毒性休克/常规治疗组病死率（%）＜70%，≥70%	总体：PMX-HP与低死亡风险相关；亚组：高死亡风险组（常规治疗组病死率≥70%），PMX-HP降低其病死率（中度异质性，证据质量偏低）

研究作者	年份	地点	研究设计	干预/样本量	类型/亚组	主要发现
Klein DJ，et al ^［25］	2018	北美	RCT	PMX-HP/450例	脓毒性休克/EAA≥0.60，0.60~0.89（MODS≥9分），≥0.90	总体：28 d病死率、EAA无差异；0.60~0.89组：PMX-HP组28 d病死率、90 d病死率更低，MAP更高、VFDs更长，并依据NE是否＞0.1 μg/（kg•min）再分亚组，NE＞0.1 μg/（kg•min）组病死率也更低
Rachoin JS，et al ^［31］	2020	北美	RCT	PMX-HP/450例	脓毒性休克/EAA≥0.6，0.6~0.9（MODS≥9分），＞0.9	总体：28 d病死率、EAA无差异；0.6~0.9组：PMX-HP组，如第3天EAA≤0.65，28 d病死率更低，如第3天EAA降幅＞10.4%（中位数），VFDs更长，PAR改善更明显
Sekino M，et al ^［32］	2023	日本	回顾性探索性观察研究	PMX-HP/122例	脓毒性休克/PAI ＜1（外周灌注正常组），≥1（外周灌注异常组）	总体：两组VIS、CVP、心率、乳酸水平降低；亚组：外周灌注正常组与异常组28 d病死率、住院病死率无差异（异常组病死率应更高），异常组PAI明显改善，正常组改善不明显（但PAI≥1组PMX-HP开始时间更早）
Garcia-Ramos S，et al ^［24］	2023	西班牙	队列研究	PMX-HP/93例	腹部脓毒性休克/SOFA（分） 0~7，8~13，＞13	总体：实际30 d病死率低于APACHE Ⅱ所预测的病死率；亚组：SOFA 8~13分组实际病死率显著低于预测病死率，而其他两组实际与预测病死率无差异。
Fujimori K，et al ^［33］	2021	日本	队列研究	PMX-HP/4066例	脓毒症/SOFA（分） 0~6，7~9，10~12，13~15，16~24	亚组：7~12分的2组28 d病死率更低，其他分组无差异；0~12分的3组无CHDF时间更长，7~12分2组VFDs、无NE时间更长；SOFA组成成分中呼吸、凝血、肝脏、心血管和肾脏高评分组（≥2分），28 d病死率更低
Lee W Y，et al ^［34］	2021	韩国	队列研究	PMX-HP/60例	腹部脓毒症（已手术）/EA＜0.54，≥0.54	总体：PMX-HP组未显示生存获益；亚组：EA≥0.54组，EA下降更明显，多因素Logistics分析显示PMX-HP对EA≥0.54组有生存益处，而对EA＜0.54组无生存益处
Fujimori K，et al ^［35］	2021	日本	队列研究	PMX-HP/8282例	脓毒性休克/NE日最大剂量（mg/d）＜6，6~9.9，10~19.9，＞20	总体：PMX-HP组28 d病死率降低，无CHDF、NE、MV天数延长；亚组：＜19.9 mg/d的3组PMX-HP有生存益处，其中10~19.9 mg/d组比值比最高，＞20 mg/d组未显示生存益处
Hawchar F，et al ^［36］	2022	多国	病例系列研究	CytoSorb/936例	脓毒症/APACHE Ⅱ（分）＜30，≥30	总体：实际ICU病死率与APACHEⅡ所预测的病死率无差异，CRP、PCT下降；亚组：15~25分组实际ICU病死率高于预测的病死率，而≥30分组实际ICU病死率低于预测
Chang T，et al ^［37］	2017	多国	Meta分析	PMX-HP/1332例	脓毒症/常规治疗组病死率（%）＜30%，30%~60%，＞60%	总体：病死率降低，但在RCT研究的分组Meta分析中未观察到此情况；亚组：中、高死亡风险组（常规治疗组病死率≥30%）病死率显著降低（但论文中病死率指标不统一，证据质量偏低）
田兴国，等^［38］	2020	多国	Meta分析	PMX-HP/926例	脓毒症/中重度脓毒性休克	总体：不能降低28 d病死率；亚组：PMX-HP治疗使中重度脓毒性休克组28 d病死率降低（仅纳入4个RCT研究，且异质性过大，且未明确中重度脓毒性休克的评价标准，证据质量偏低）
Chen JJ，et al ^［39］	2023	多国	网状Meta分析	17种方式/4595例	严重感染、脓毒症、脓毒性休克/常规治疗组病死率（%）＜70%，≥70%	总体：PMX-HP与低死亡风险相关；亚组：高死亡风险组（常规治疗组病死率≥70%），PMX-HP降低其病死率（中度异质性，证据质量偏低）

[1]	Yuze Xing, Quan Li, Shengjun Cao. Research progress of multi-omics technologies in the diagnosis and treatment of burn-associated sepsis [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2026, 21(03): 223-228.
[2]	Hongfei Deng, Ke Feng, Zheng Wang, Wenkai Jang, Xiaoting Zhang. Short-term efficacy of anisodamine hydrobromide (654-1) combined with blood purification therapy in patients with septic shock [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2026, 20(01): 31-38.
[3]	Fang Zhou, Haichen Liu, Yuchao Wang, Jian Guo, Zhiliang Shi, Guoqiang Zhou, Chenglong Shen. Clinical application of "three-hole method" laparoscopic surgery in the treatment of acute sigmoid colon perforation [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2026, 20(02): 154-157.
[4]	Hongbo Xu, Yuliang Hu, Xuedong Wei, Lichen Jin, Kefeng Wu, Yilun Chen, Bing Lu, Shoujun Zhou, Jianquan Hou. The predictive value of machine learning models based on clinical and CT radiomics features for sepsis after percutaneous nephrolithotomy [J]. Chinese Journal of Endourology(Electronic Edition), 2026, 20(03): 297-306.
[5]	Kang He, Cheng Yang, Cundong Liu. Application of transvesical laparoendoscopic single-site surgery in urology [J]. Chinese Journal of Endourology(Electronic Edition), 2026, 20(02): 140-146.
[6]	Xiao Li, Xiaolong Pan, Jianzhou Cheng, Shizhong Zhang, Guangjian Zhu, Ziliang Deng, Fanyu Wu. A retrospective cohort study of risk factors in patients with urosepsis complicating upper urinary tract stones after surgery [J]. Chinese Journal of Endourology(Electronic Edition), 2026, 20(02): 165-170.
[7]	Guochen Liu, Jiawei An, Junyu Zhu, Weihong Dai, Fen Li. Advances in the mechanisms of lipocalin-2 in sepsis [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2026, 16(03): 162-169.
[8]	Pingping Xu, Danyang Song, Xiao Li, Hui Li, Xia Wang. Stratification value of combined scoring of procalcitonin and amino-terminal pro-B-type natriuretic peptide on the efficacy of methylprednisolone combining integrated blood purification in children with severe sepsis [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2026, 15(02): 93-99.
[9]	Wanyi Chen, Fei Pei, Jianfeng Wu. Precision immunotherapy for sepsis in 2025 [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(02): 112-117.
[10]	Nan Shi, Ruixuan Yu, Jianfeng Xie, Haibo Qiu. Disease burden and current research status in sepsis with chronic comorbidities [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(01): 7-14.
[11]	Yin Xi, Yanchun Gao, Weilin Wang, Yonghao Xu. Individualized fluid resuscitation in sepsis with chronic comorbidities: an organ reserve capacity-guided approach [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(01): 15-20.
[12]	Qianhui Chen, Zhigang Cui, Jinhe Sun, Renyu Ding. Multivariate prognostic analysis and construction of a prognostic model for sepsis-associated severe thrombocytopenia [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(01): 53-66.
[13]	Zhong Wang, Zhaotian Guo, Qianhui Chen, He Miao, Wanting Su, Renyu Ding. Effect of platelet transfusion on the prognosis of patients with sepsis-associated severe thrombocytopenia [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(01): 67-75.
[14]	Jinyuan Li, Hanyu Mai, Kai Chen, Wenyan Zhou, Jijia Bai, Xiangyuan Cao, Huan Ding. Research progress on the mechanism of protein-anabolic resistance leading to decreased skeletal muscle mass in elderly sepsis [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(01): 93-100.
[15]	Guomin Ou, Qishui Ou. Laboratory biomarkers in chronic hepatitis B: Evidence base, clinical applications, and management strategies [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2026, 14(02): 157-165.

Please choose a citation manager

Content to export